# Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

> **NCT03409107** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 614 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** Daprodustat (GSK1278863)
- **DRUG:** Placebo
- **DRUG:** Iron therapy

## Key facts

- **NCT ID:** NCT03409107
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2020-10-07
- **Final completion:** 2020-10-07
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409107, "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03409107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*